Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

U.S. delivers over 25 million COVID boosters; Moderna's shot in limited supply

Published 09/20/2022, 03:35 PM
Updated 09/20/2022, 07:25 PM
© Reuters. FILE PHOTO: A nurse fills up syringes with the coronavirus disease (COVID-19) vaccines for residents who are over 50 years old and immunocompromised and are eligible to receive their second booster shots in Waterford, Michigan, U.S., April 8, 2022.  REUTE

(Reuters) -The United States government has sent out over 25 million of the updated COVID-19 booster shots, mostly from Pfizer/BioNTech, as production of the Moderna (NASDAQ:MRNA) shot continues to ramp up, a federal health agency said on Tuesday.

Some U.S. pharmacies like CVS Health (NYSE:CVS) and Walgreens Boots Alliance (NASDAQ:WBA) also reported on Tuesday that government supply of Moderna's updated shot remains limited, causing appointments for the product to vary across the country.

In a statement late on Tuesday, the U.S. Food and Drug Administration (FDA) said it authorized ten batches of Moderna's updated booster shots made at a Catalent (NYSE:CTLT) facility in Indiana after it deemed them safe to use. It did not provide details on the number of doses cleared.

The Catalent facility is currently not authorized by the FDA to manufacture Moderna's updated booster shots and the regulator said the company requested it to authorize these batches in light of the current supply issues.

Both CVS and Walgreens said they are working with the government to acquire more Moderna doses and have not seen any supply issues for the Pfizer/BioNTech booster.

In August, the FDA authorized Pfizer (NYSE:PFE) and Moderna's updated booster shots that target the dominant BA.4 and BA.5 Omicron subvariants, as the country prepares for a broad fall revaccination campaign.

According to the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR), retail pharmacies will be receiving millions more doses of Moderna this week and that production is ramping up.

"We anticipate supply will continue to increase in the coming weeks," an ASPR spokesperson told Reuters.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Moderna said it is working closely with the U.S. government to deliver significant amounts of the updated, bivalent booster doses and anticipates that these availability constraints will be resolved in the coming days. It said it expects to ship the 70 million doses by the end of the year, as promised in its contract.

The U.S. has ordered more than 170 million updated vaccine booster shots for this fall when all individuals aged 12 and over who have already received the initial doses of the vaccine are being encouraged to receive a booster shot.

Latest comments

Why more shots? The prez said the pandemic is over. Maybe he wasnt having one of his good days
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.